BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 20583901)

  • 1. Estrogen reduces BDNF level, but maintains dopaminergic cell density in the striatum of MPTP mouse model.
    Tripanichkul W; Gerdprasert O; Jaroensuppaperch EO
    Int J Neurosci; 2010 Jul; 120(7):489-95. PubMed ID: 20583901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinson's disease.
    Al-Sweidi S; Morissette M; Bourque M; Di Paolo T
    Neuropharmacology; 2011 Sep; 61(4):583-91. PubMed ID: 21586296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.
    Holmer HK; Keyghobadi M; Moore C; Menashe RA; Meshul CK
    Synapse; 2005 Aug; 57(2):100-12. PubMed ID: 15906381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
    Liu LX; Chen WF; Xie JX; Wong MS
    Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum.
    Xu G; Xiong Z; Yong Y; Wang Z; Ke Z; Xia Z; Hu Y
    Neuroscience; 2010 Apr; 167(1):174-84. PubMed ID: 20123001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice.
    Sun L; Xu S; Zhou M; Wang C; Wu Y; Chan P
    Brain Res; 2010 Jun; 1335():74-82. PubMed ID: 20380823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2008 Aug; 28(3):610-7. PubMed ID: 18702732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of the number and phenotype of striatal dopaminergic cells by carotid body graft.
    San Sebastián W; Guillén J; Manrique M; Belzunegui S; Ciordia E; Izal-Azcárate A; Garrido-Gil P; Vázquez-Claverie M; Luquin MR
    Brain; 2007 May; 130(Pt 5):1306-16. PubMed ID: 17439984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication.
    Tripanichkul W; Sripanichkulchai K; Finkelstein DI
    Brain Res; 2006 Apr; 1084(1):28-37. PubMed ID: 16564034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
    Schmidt N; Ferger B
    Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of brain-derived neurotrophic factor as a potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model.
    Bousquet M; Gibrat C; Saint-Pierre M; Julien C; Calon F; Cicchetti F
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1401-8. PubMed ID: 19632286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action.
    Schober A; Peterziel H; von Bartheld CS; Simon H; Krieglstein K; Unsicker K
    Neurobiol Dis; 2007 Feb; 25(2):378-91. PubMed ID: 17141511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.
    Ohashi S; Mori A; Kurihara N; Mitsumoto Y; Nakai M
    Neurosci Lett; 2006 Jun; 401(1-2):183-7. PubMed ID: 16581184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice.
    D'Astous M; Morissette M; Tanguay B; Callier S; Di Paolo T
    Synapse; 2003 Jan; 47(1):10-4. PubMed ID: 12422368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
    Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW
    Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen Increases Striatal GDNF Immunoreactivity with no Effect on Striatal FGF-2 Immunoreactivity of MPTP-Treated Mice.
    Tripanichkul W; Jaroensuppaperch EO
    J Med Assoc Thai; 2015 Oct; 98 Suppl 9():S16-22. PubMed ID: 26817205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of donor age and brain-derived neurotrophic factor on the survival of dopaminergic neurons and axonal growth in postnatal rat nigrostriatal cocultures.
    Ostergaard K; Jones SA; Hyman C; Zimmer J
    Exp Neurol; 1996 Dec; 142(2):340-50. PubMed ID: 8934565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.